Intralymfatisk allergenspecifik immunterapi

Sara Haunstrup Næraa, Niels Erik Harbo Schollert, Peter Nytofte Flader Skov, Preben Homøe

Publikation: Bidrag til tidsskriftReviewForskningpeer review


An emerging method for allergen-specific immunotherapy is intralymphatic placement, which only requires three injections with intervals of four weeks. In this review, we summarise available evidence on clinical safety, biological efficacy and therapeutic outcomes. The treatment appears to be safe with only few and mild adverse reactions. The immunological activation profile is comparable to that known for subcutaneous therapy. Clinically, patients experienced fewer symptoms with less medication use with intralymphatic allergen-specific immunotherapy than with other types of immunotherapy. The number of studies is limited, and the studies have important limitations. More phase 3 studies are needed in order to make a conclusion.

Bidragets oversatte titelIntralymphatic allergen-specific immunotherapy
Sider (fra-til)144-147
Antal sider4
TidsskriftUgeskrift for laeger
Udgave nummer2
Tidlig onlinedato28 maj 2018
StatusUdgivet - 21 jan. 2019


  • Allergens/administration & dosage
  • Desensitization, Immunologic/methods
  • Humans
  • Injections, Intralymphatic/methods
  • Rhinitis, Allergic/therapy
  • Treatment Outcome


Udforsk hvilke forskningsemner 'Intralymfatisk allergenspecifik immunterapi' indeholder.